Prenosis is at the forefront of precision medicine in acute care, utilizing its Immunix™ platform to enhance the understanding of patient biology and improve treatment outcomes. The Immunix™ platform is designed to develop and validate precision medicine tools, enabling real-time integration into clinical workflows. This platform has generated the world's largest biomarker-clinical dataset for infections in acute care, leveraging machine learning algorithms to provide comprehensive insights into patients' biological states. By focusing on individual biology rather than traditional symptom-based diagnoses, Prenosis aims to empower healthcare providers to tailor treatments to the unique needs of each patient.

A key innovation from Prenosis is the Sepsis ImmunoScore™, which is the first FDA-authorized AI diagnostic tool for sepsis. This diagnostic integrates clinical data and biomarkers to deliver real-time assessments of a patient's risk for sepsis and potential adverse outcomes within 24 hours. The Sepsis ImmunoScore™ is designed for seamless integration into hospital Electronic Medical Records (EMRs), facilitating timely interventions that can enhance patient outcomes and reduce hospital costs. By providing critical information and transparency in its scoring methodology, Prenosis is transforming the approach to diagnosing and managing sepsis in acute care settings.

United States

Prenosis, decision support tools use artificial intelligence to rapidly synthesize proprietary biological data and historical clinical data to predict future outcomes

Prenosis

Company Details